Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
EverLife Biomed logo — Pioneering the future of human-derived immune cell technolog...

EverLife Biomed

Pioneering the future of human-derived immune cell technology with proprietary innovations since 2018.

Founded 2018 Venture round Biotechnology, Health Care

General Information

Company Name EverLife Biomed
Founded Year 2018
Industries Biotechnology, Health Care
Funding Stage Venture round
Social

BounceWatch is an independent company data service, not affiliated with EverLife Biomed. To contact EverLife Biomed, visit everlifebiomed.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

About EverLife Biomed

EverLife Biomed is a trailblazing company that is pioneering the future of human-derived immune cell technology with proprietary innovations since 2018. Based in Haidian, Beijing, China, the company is focused on the biotechnology and healthcare industries. Founded in 2018, EverLife Biomed has developed the first human-derived immune exempt cell technology with completely independent intellectual property rights. The company has successfully attracted Venture Round investment in January 2019, with Tsinghua Innovation Ventures and UnityVC as the participating investors. This financing round underscores the confidence of prominent investors in the potential of EverLife Biomed's innovative approach to human-derived immune cell technology.

Taxonomy: Immune cell technology, Human-derived technology, Intellectual property rights, Cell therapy, Biomedical innovation

Funding Rounds & Investors (1)

View All
Funding Stage Amount Investors Lead Investors Date
Venture Round Undisclosed 2
Tsinghua Innovation Ventures
Tsinghua Innovation Ventures, UnityVC
01 Jan 2019

EverLife Biomed Alternatives & Competitors

EverLife Biomed vs
Omniscope
Omniscope United States

Science is we all.

Growth
39 employees
AI, Big Data
EverLife Biomed vs
Tr1X
Tr1X United States

Engineering cures for patients with autoimmune & inflammatory diseases.

46 employees
Biotechnology, Health Care
EverLife Biomed vs
CytoTrack
CytoTrack

Discover the Future of Tumor Cell Detection with Unparalleled Precision and Speed

Grant
Biotechnology, Health Care

FAQ About EverLife Biomed

Pioneering the future of human-derived immune cell technology with proprietary innovations since 2018.
EverLife Biomed was founded in 2018.
EverLife Biomed operates in Biotechnology and Health Care. Its work centres on Immune cell technology, Human-derived technology, Intellectual property rights and Cell therapy.
EverLife Biomed has completed 1 funding round. The latest funding stage is Venture round.
Top alternatives and competitors to EverLife Biomed include Omniscope, Tr1X, CytoTrack, Histide, ClonOrgan. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
EverLife Biomed and Omniscope are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for EverLife Biomed, https://bouncewatch.com/company/everlife-biomed, updated 11 October 2024. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Book a demo 30 minutes